Evaluating the costs and benefits of pneumococcal vaccination in adults

Porchia, Barbara Rita; Bonanni, Paolo; Bechini, Angela; Bonaccorsi, Guglielmo; Boccalini, Sara

doi:10.1080/14760584.2017.1242419

Cited by 20 publications

(20 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccination programs will become increasingly important around the world in the future due to the constant aging of the population, and prevention may reduce the burden of pneumococcal diseases on health systems and the consequent incremental social costs. In light of these considerations, pneumococcal vaccines are a paradigmatic example of a clear and effective trade-off between benefits and costs [ 95 , 96 ]. PCV13 and PPV23 have an excellent value for money and should become a real priority for decision makers in public health [ 97 ].…”

Section: Medical Costsmentioning

confidence: 99%

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

et al. 2021

View full text Add to dashboard Cite

Streptococcus pneumoniae related diseases are a leading cause of morbidity and mortality, especially in children and in the elderly population. It is transmitted to other individuals through droplets and it can spread to other parts of the human host, causing a wide spectrum of clinical syndromes, affecting between 10 and 100 cases per 100,000 people in Europe and the USA. In order to reduce morbidity and mortality caused by this agent, pneumococcal vaccines have been developed over the years and have shown incredible effectiveness in reducing the spread of this bacterium and the development of related diseases, obtaining a significant reduction in mortality, especially in developing countries. However, considerable problems are emerging mainly due to the replacement phenomenon, multi-drug resistance, and the high production costs of conjugated vaccines. There is still a debate about the indications given by various countries to different age groups; this is one of the reasons for the diffusion of different serotypes. To cope with these problems, significant efforts have been made in the research field to further improve vaccination serotypes coverage. On the other hand, an equally important commitment by health care systems to all age group populations is needed to improve vaccination coverage.

show abstract

Section: Medical Costsmentioning

confidence: 99%

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…40 This study also revealed alcohol abuse as a risk factor for mortality. Pneumococcal vaccination with PCV13 or PPV23 in adults is cost-effective and should be considered a priority for decision-makers, 41 and status of vaccination varied widely among studies (0-54.5%). Pneumonia vaccination was another effective means of preventing IPD, but much work remains to be done to increase the acceptance of pneumonia vaccination.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for mortality in invasive pneumococcal disease: a system review and meta-analysis

Chen

Matsumoto

Horita

et al. 2021

Preprint

View full text Add to dashboard Cite

Risk factors associated with mortality in invasive pneumococcal disease remain unclear. The present work is a meta-analysis of studies that enrolled only patients with invasive pneumococcal disease and reported on mortality. Potentially eligible reports were identified from PubMed, CHAHL, and Web of Science, comprising 26 reports in total. Overall mortality for invasive pneumococcal disease was reported as 20.8% (95% confidence interval (CI) 17.5–24%). Factors associated with mortality were age (odds ratio (OR) 3.04, 95%CI 2.5–3.68), nursing home (OR 1.62, 95%CI 1.13–2.32), nosocomial infection (OR 2.10, 95%CI 1.52–2.89), septic shock (OR 13.35, 95%CI 4.54–39.31), underlying chronic diseases (OR 2.34, 95%CI 1.78–3.09), solid organ tumor (OR 5.34, 95%CI 2.07–13.74), immunosuppressed status (OR 1.67, 95%CI 1.31–2.14), and alcohol abuse (OR 3.14, 95%CI 2.13–4.64). Mortality rates with invasive pneumococcal disease remained high, and these findings may help clinicians provide appropriate initial treatment for this disease.Key points: The overall mortality rate from IPD has remained high, at 20.8% and older age, septic shock, immunosuppressed status, underlying chronic diseases, solid organ tumor, alcohol abuse, nursing home, and nosocomial infection were prognostic factors for mortality from IPD.

show abstract

“…Emergent admission to ICU is a strong predictor of subsequent critical illness 14 ; both the acute care costs and future costs related to worsening chronic health burden in this cohort are high 15 . The health economics would seem to strongly support making all reasonable efforts to improve modifiable health factors in this population 16 .…”

Section: Discussionmentioning

confidence: 99%

Primary Prevention in the Intensive Care Unit: A Prospective Single-Centre Study of the Risk Factors for Invasive Pneumococcal Disease

Chapman

Litton

2017

Anaesth Intensive Care

View full text Add to dashboard Cite

Invasive pneumococcal disease is a significant health burden in Australia, with immunisation recommended for children and at-risk adults. Health benefits of immunisation are clear, but less effective when immunisation rates are low, as in Western Australia. We hypothesised that patients admitted unplanned to the intensive care unit (ICU) would have high eligibility for pneumococcal immunisation, but low rates of recorded vaccine administration. We performed a prospective observational study of 119 emergency admissions to Royal Perth ICU, a 20-bed mixed ICU at a tertiary teaching hospital in Western Australia. Each admission was screened for vaccine eligibility (age and risk factors as per Australian Technical Advisory Group of Immunisation guidelines), with patients' health records examined and primary care providers contacted after ICU discharge. Risk factors for invasive pneumococcal disease were common, with 52% of the study population having one or more. Fifty-four of 119 admitted patients (45%) were assessed as eligible for immunisation after ICU discharge. ICU survivors represent a highrisk population for which intervention against modifiable targets, such as invasive pneumococcal disease, may reduce both their chronic health burden and future health expenditure. Future efforts should concentrate on assessing the feasibility of a screening program for modifiable factors in ICU survivors, and the logistics of delivering these interventions in a timely manner during their hospital stay.

show abstract

Evaluating the costs and benefits of pneumococcal vaccination in adults

Cited by 20 publications

References 45 publications

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

Prognostic factors for mortality in invasive pneumococcal disease: a system review and meta-analysis

Primary Prevention in the Intensive Care Unit: A Prospective Single-Centre Study of the Risk Factors for Invasive Pneumococcal Disease

Contact Info

Product

Resources

About